This story is currently available in anglais only — a translation isn't ready yet.
Stopping weight-loss jabs linked to doubled heart attack and stroke risk
Italian study of more than 80,000 people with type 2 diabetes finds the combined rate of non-fatal heart attack, non-fatal stroke or death was around twice as high after discontinuation
ℹ️ Lecture par le navigateur · voix studio IA bientôt

People with type 2 diabetes who stop taking GLP-1 medicines face roughly twice the combined rate of non-fatal heart attack, non-fatal stroke or death from any cause as those who stay on them, a study of Italian patient records has found.
The research, published in The Lancet Regional Health - Europe in November 2024, examined the records of more than 80,000 people with type 2 diabetes at 301 diabetes clinics in Italy, none of whom had established cardiovascular disease when the study began. It analysed records spanning 2004 to 2024.
Those who continued treatment used the drugs for nearly three years on average, against just over a year among those who stopped. The association appeared stronger among people who remained obese after stopping treatment, and the increased risk was not fully explained by changes in weight, blood sugar or blood pressure.
The study did not establish why people stopped taking the medication, a limitation the researchers flagged. Dr Francesco Lo Monaco, a cardiologist and founder of the National Longevity Clinic, said the findings suggest the benefits of treatment may extend beyond weight loss and blood sugar control. "We need to be very careful about interpreting them," he said.
He said the study was observational. "It cannot prove that stopping the medication caused the higher risk," he said. People may have stopped because they were already becoming unwell, or for other reasons that also affected their health, he added.
Patients should speak to their treating clinician before stopping or changing treatment, Dr Lo Monaco said, and the study is not evidence that everyone taking a GLP-1 medicine must remain on it indefinitely. More than 1.5 million people across the UK are estimated to be taking some form of weight loss injection. The researchers said further studies are needed to establish whether stopping GLP-1 treatment directly affects cardiovascular risk, or whether the association reflects differences in the health of people who discontinue it.
Sources — how we know this
- PrimaryDaily Mirror — News